Table 2.

Characteristics of MCL patients


Patient no.

Disease status

Cell source*

Morphologic variant

% of tumoral cells

p53 status
1   Diagnosis   PB   C   95   wt  
2   Relapse   PB   C   95   CGT→CAT (codon 273)  
3   Diagnosis   PB   C   84   wt  
4   Diagnosis   PB   C   85   wt  
5   Diagnosis   Spleen   C   95   wt  
6   Diagnosis   Spleen   C   80   wt  
7   Diagnosis   PB   C   86   wt  
8   Relapse   PB   B   70   wt  
9   Diagnosis   Spleen   C   95   wt  
10
 
Diagnosis
 
PB
 
C
 
75
 
wt
 

Patient no.

Disease status

Cell source*

Morphologic variant

% of tumoral cells

p53 status
1   Diagnosis   PB   C   95   wt  
2   Relapse   PB   C   95   CGT→CAT (codon 273)  
3   Diagnosis   PB   C   84   wt  
4   Diagnosis   PB   C   85   wt  
5   Diagnosis   Spleen   C   95   wt  
6   Diagnosis   Spleen   C   80   wt  
7   Diagnosis   PB   C   86   wt  
8   Relapse   PB   B   70   wt  
9   Diagnosis   Spleen   C   95   wt  
10
 
Diagnosis
 
PB
 
C
 
75
 
wt
 

PB indicates peripheral blood; C, classical; and B, blastoid.

*

Source of the cells used for the in vitro analysis

p53 status assessed by fluorescence in situ hybridization (FISH) and mutational status analyzed bysingle-strand conformation polymorphism (SSCP) and sequencing

or Create an Account

Close Modal
Close Modal